Downregulated expression levels of LINC01619 are associated with proteinuria and declines in kidney function in DN patients; hence, targeting LINC01619 is one of the potential therapeutic options for treatment of DN [51]. This evidence concerns the gene LINC01619 and liver dysplastic nodule.